Samsung Biologics Competitors and Similar CompaniesClear all
Samsung Biologics's competitors and similar companies include Pharmaron, WuXi Biologics, Catalent and PPD.
 Samsung Biologics Samsung Biologics (삼성바이오로직스) is a contract development and manufacturing organization. |  Pharmaron Pharmaron (康龙化成（北京）新药技术股份有限公司) is a company that provides contract research, development, and manufacturing services for pharmaceutical products. |  WuXi Biologics WuXi Biologics (药明生物) is a company operating as an open-access technology platform for biologics drug development. |  Catalent Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products. |  PPD PPD (Pharmaceutical Product Development) is a company that provides drug development and laboratory solutions. | |
Founding Date | Founding Date 2011 | Founding Date 2004 | Founding Date 2010 | Founding Date 2007 | Founding Date 1985 |
Type | Type Public | Type Public | Type Public | Type Private | Type Subsidiary |
Tags | |||||
Locations | Locations Incheon, KR HQ Boston, US Ridgefield Park, US South San Francisco, US | Locations Wuxi, CN HQ George Town, KY Wuppertal, DE Hong Kong, HK Dundalk, IE Cranbury, US King Of Prussia, US | Locations Somerset, US HQ Buenos Aires, AR Bruxelles, BE Charleroi, BE Charleroi, BE Charleroi, BE Indaiatuba, BR see more | Locations Wilmington, US HQ Buenos Aires, AR Melbourne, AU Brussels, BE Zaventem, BE São Paulo, BR São Paulo, BR see more | |
Employees | Employees 4,7705% increase | Employees 20,295 | Employees 12,435 | Employees 16,9005% decrease | Employees 25,5521% decrease |
Financial | |||||
Revenue (est.) | Revenue (est.) ₩4.5t (FY, 2024) | Revenue (est.) ¥12.2b (FY, 2024) | Revenue (est.) ¥18.7b (FY, 2024) | Revenue (est.) $4.4b (FY, 2024) | Revenue (est.) $4.7b (FY, 2020) |
Cost of goods | Cost of goods ₩1.7t (FY, 2024) | Cost of goods ¥8.1b (FY, 2024) | Cost of goods ¥9.4b (FY, 2024) | Cost of goods $3.4b (FY, 2024) | Cost of goods $1.7b (FY, 2020) |
Gross profit | Gross profit ₩2.8t (FY, 2024) | Gross profit ¥4.1b (FY, 2024) | Gross profit ¥9.5b (FY, 2024) | Gross profit $953m (FY, 2024) | Gross profit $3b (FY, 2020) |
Net income | Net income ₩1.1t (FY, 2024) | Net income ¥1.7b (FY, 2024) | Net income ¥3.9b (FY, 2024) | Net income ($1b) (FY, 2024) | Net income $160.6m (FY, 2020) |
Operating ⚠ | |||||
Backlog | Backlog N/A | Backlog N/A | Backlog $18.5b (H1, 2022) | Backlog $2.5b (FY, 2023) | Backlog $9.5b (Q3, 2021) |
Countries | Countries N/A | Countries N/A | Countries N/A | Countries 80 (FY, 2023) | Countries 46 (FY, 2020) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 909m | Total funding raised N/A | Total funding raised $ 650m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Pharmaron
HQ
Beijing, CN
Employees
20,295
Pharmaron (康龙化成（北京）新药技术股份有限公司) is a company that provides contract research, development, and manufacturing services for pharmaceutical products.
View companyWuXi Biologics
HQ
Wuxi, CN
Employees
12,435
WuXi Biologics (药明生物) is a company operating as an open-access technology platform for biologics drug development.
View companyCatalent
HQ
Somerset, US
Employees
16,900↓ 5% decrease
Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products.
View companyPPD
HQ
Wilmington, US
PPD (Pharmaceutical Product Development) is a company that provides drug development and laboratory solutions.
View company